Omburtamab
- Generic Name
- Omburtamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1895083-75-6
- Unique Ingredient Identifier
- XQL6783S5T
- Background
CD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours. Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers.
Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/leptomeningeal Metastases).
- Associated Conditions
- -
- Associated Therapies
- -
Leptomeningeal Metastases Treatment Market 2034
The Leptomeningeal Metastases market, involving companies like Plus Therapeutics and AstraZeneca, is projected to grow significantly by 2034. Key therapies include Rhenium-186 NanoLiposome and AZD1390. The market report covers treatment practices, emerging drugs, and forecasts, highlighting the need for improved therapies and supportive care strategies.
To Make America Healthy Again, FDA Must Cut Red Tape
Trump's campaign focused on expanding consumer and patient choice, including the 'Right to Try' law for terminally ill patients. Key ally RFK Jr. advocates for more FDA rules despite evidence of their ineffectiveness. The FDA's rejection of drugs like omburtamab and zolbetuximab, despite their potential benefits, highlights a need for reform. The FDA's approval process lags behind international standards, even with priority review. Accelerated approval programs have shown success, suggesting the need for their expansion and critical review of rejections.
Michael Wernke is Fighting Corporate Malfeasance – and Winning Big for Investors
Pomerantz partner Michael Wernke led high-profile securities fraud cases against Teva Pharmaceuticals, Y-mAbs Therapeutics, and Nikola Corp., securing favorable settlements and refining legal strategies for future cases.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath